This GMS Flash Alert reports on a new Circular that introduced pilot administrative measures for health insurance products qualifying for preferential individual income tax (IIT) treatment.
The China Insurance Regulatory Commission (CIRC) issued Circular 821 which introduced pilot administrative measures for health insurance products qualifying for preferential individual income tax (IIT) treatment (“IIT-preferential health insurance policies”).
Circular 82 became effective 10 August 2015.
The extension of preferential IIT treatment for a broader range of qualifying health insurance products should encourage individuals (and their employers) to take out insurance policies to help them meet their health coverage needs, get more people covered by health insurance, and offer tax-savings potential.
CIRC issued Bao Jian Fa  No. 82 (“Circular 82”) introducing pilot administrative measures for health insurance products that will qualify for preferential IIT treatment as prescribed in the Notice on Individual Income Tax Treatment on Commercial Health Insurance (Cai Shui  No.56).2
Circular 82 makes it clear that IIT-preferential health insurance policies are those commercial health insurance products issued in accordance with Circular 82 and purchased by individuals in the specified pilot cities. Life insurance companies and their affiliates (collectively called insurance companies) that engage in the business of IIT-preferential health insurance policies should satisfy the requirements as stated in Circular 82.
The CIRC will shortly release a list of the qualified insurance companies and update the list regularly.
Circular 82 elaborates on the types of insurance policies qualifying for preferential IIT treatment, and introduces detailed administrative measures for these policies:
Insurance companies should issue receipts designed specifically for IIT preferential health insurance policies to policy-holders as proof for the IIT deduction after receiving insurance premiums.
In addition, Circular 82 provides specific administrative measures on the financial management, information system management, information disclosure, and supervision of insurance companies.
Cai Shui  No.56 provides that taxpayers in the pilot cities who earn income from the following sources will be eligible to claim a tax deduction in the amount of the premium they pay for qualified commercial health insurance products against the respective categories of assessable income:
A cap of RMB 2,400 per year (or RMB 200 per month) has been set as the maximum amount of tax deduction allowed in respect of the relevant premiums paid.
Circular 82 clarifies the criteria for those health insurance policies that will qualify for preferential IIT treatment in the pilot cities and has sped up the implementation of policies on commercial health insurance products qualifying for preferential IIT treatment.
The KPMG International member firm in the People’s Republic of China (“KPMG”) anticipates that qualified insurance companies will gradually roll out several IIT-preferential health insurance policies to the market in the near future.
Employers should keep a close watch on the list of qualified insurance companies to be announced by the CIRC, and make a considered assessment of such so that informed decisions can be taken on the selection of appropriate commercial health insurance products for their employees – and thus, make proper use of the preferential tax treatment available to them, and, if appropriate, adjust their remuneration packages.
Also, KPMG recommends that companies confirm the "个人税优健康保险" status of the commercial health insurance policies when selecting IIT-preferential health insurance policies for their employees, and obtain IIT-preferential health insurance receipts from the insurance company for IIT deduction purposes.
1 Notice on Pilot Admin Measures on the Health Insurance Products Qualified for Individual Income Tax Preferential Treatments, Bao Jian Fa  No.82, issued by the China Insurance Regulatory Commission on 10 August 2015.
2 For prior coverage, see GMS Flash Alert 2015-071 (4 June 2015).
This article is excerpted with permission from “Updates on Health Insurance Products Qualified for Preferential IIT Treatment,” in China Tax Alert (Issue 23, September 2015), a publication of the KPMG International member firm in the People’s Republic of China.
For the English-language version, click here.
For the Chinese-language version, click here.
For additional information or assistance, please contact your local GMS or People Services professional or one of the following professionals with the KPMG International member firm in the People’s Republic of China:
Tel. +86 21 2212 3458
Tel. +86 (21) 2212 2888 ext 3527
The information contained in this newsletter was submitted by the KPMG International member firm in the People’s Republic of China.
© 2020 KPMG Advisory (China) Limited, a wholly foreign owned enterprise in China and KPMG Huazhen, a Sino-foreign joint venture in China, are member firms of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved.
KPMG International Cooperative (“KPMG International”) is a Swiss entity. Member firms of the KPMG network of independent firms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm.
Flash Alert is an Global Mobility Services publication of KPMG LLPs Washington National Tax practice. The KPMG logo and name are trademarks of KPMG International. KPMG International is a Swiss cooperative that serves as a coordinating entity for a network of independent member firms. KPMG International provides no audit or other client services. Such services are provided solely by member firms in their respective geographic areas. KPMG International and its member firms are legally distinct and separate entities. They are not and nothing contained herein shall be construed to place these entities in the relationship of parents, subsidiaries, agents, partners, or joint venturers. No member firm has any authority (actual, apparent, implied or otherwise) to obligate or bind KPMG International or any member firm in any manner whatsoever. The information contained in herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.